Amarin Posts New Data Showing Benefit of Vascepa In High-Risk Patients With Acute Coronary Syndrome

Amarin Corporation plc AMRN announced a new analysis from the Vascepa/Vazkepa (icosapent ethyl) cardiovascular outcomes REDUCE-IT study.
The study exhibited the effectiveness of Vascepa/Vazkepa in patients with the recent acute coronary syndrome.
The post-hoc analysis showed that icosapent ethyl (IPE) substantially and significantly reduced the risk of first and total ischemic events by 37% and 36%, respectively, in patients with the recent acute coronary syndrome (ACS) without increasing bleeding, supporting early initiation of IPE after ACS.
Related: Amarin Calls Activist Investor, Largest Shareholder Sarissa's Statement 'Inaccurate, Misleading'
In this post hoc ACS analysis of the landmark REDUCE-IT study, 840 patients who experienced recent ACS were compared to 3,651 patients with ACS ≥12 months before randomization.
The absolute risk reduction for first events with IPE treatment over five years for the primary composite endpoint was 9.3%, with a number needed to treat (NNT) of 11.
The absolute risk reduction for first events with IPE treatment in patients with ACS ≥12 months was 4.7% with an NNT of 21.
Overall tolerability and adverse event patterns with IPE and placebo in patients with recent ACS were consistent with the full study. Bleeding event rates were no more frequent with IPE than placebo despite extensive use of dual antiplatelet therapy.
Price Action: AMRN shares are up 1.54% at $1.98 premarket on the last check Monday.